Vivozon Healthcare Inc (082800) - Net Assets
Based on the latest financial reports, Vivozon Healthcare Inc (082800) has net assets worth ₩72.66 Billion KRW (≈ $49.24 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩165.48 Billion ≈ $112.14 Million USD) and total liabilities (₩92.82 Billion ≈ $62.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vivozon Healthcare Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩72.66 Billion |
| % of Total Assets | 43.91% |
| Annual Growth Rate | 2.46% |
| 5-Year Change | -14.63% |
| 10-Year Change | 219.51% |
| Growth Volatility | 91.68 |
Vivozon Healthcare Inc - Net Assets Trend (2009–2025)
This chart illustrates how Vivozon Healthcare Inc's net assets have evolved over time, based on quarterly financial data. Also explore 082800 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Vivozon Healthcare Inc (2009–2025)
The table below shows the annual net assets of Vivozon Healthcare Inc from 2009 to 2025. For live valuation and market cap data, see 082800 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩72.66 Billion ≈ $49.24 Million |
-31.72% |
| 2024-12-31 | ₩106.43 Billion ≈ $72.12 Million |
+2.27% |
| 2023-12-31 | ₩104.07 Billion ≈ $70.52 Million |
-1.67% |
| 2022-12-31 | ₩105.84 Billion ≈ $71.72 Million |
+24.34% |
| 2021-12-31 | ₩85.12 Billion ≈ $57.68 Million |
-21.04% |
| 2020-12-31 | ₩107.80 Billion ≈ $73.06 Million |
-1.10% |
| 2019-12-31 | ₩109.00 Billion ≈ $73.87 Million |
+59.24% |
| 2018-12-31 | ₩68.45 Billion ≈ $46.38 Million |
+325.14% |
| 2017-12-31 | ₩16.10 Billion ≈ $10.91 Million |
-29.21% |
| 2016-12-31 | ₩22.74 Billion ≈ $15.41 Million |
-7.75% |
| 2015-12-31 | ₩24.65 Billion ≈ $16.71 Million |
-27.27% |
| 2014-12-31 | ₩33.90 Billion ≈ $22.97 Million |
-39.63% |
| 2010-12-31 | ₩56.15 Billion ≈ $38.05 Million |
+14.05% |
| 2009-12-31 | ₩49.23 Billion ≈ $33.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vivozon Healthcare Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111108.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩376.46 Billion | 518.07% |
| Total Equity | ₩72.66 Billion | 100.00% |
Vivozon Healthcare Inc Competitors by Market Cap
The table below lists competitors of Vivozon Healthcare Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eightco Holdings Inc.
NASDAQ:ORBS
|
$163.01 Million |
|
Shenyang Cuihua Gold and Silver Jewelry Co Ltd
SHE:002731
|
$163.05 Million |
|
Immunic Inc
NASDAQ:IMUX
|
$163.08 Million |
|
Precision Camshafts Limited
NSE:PRECAM
|
$163.09 Million |
|
Empresas Iansa S.A
SN:IANSA
|
$162.84 Million |
|
Enea AB
ST:ENEA
|
$162.84 Million |
|
Onewater Marine
NASDAQ:ONEW
|
$162.81 Million |
|
Shaniv
TA:SHAN
|
$162.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivozon Healthcare Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 106,426,761,450 to 72,664,636,240, a change of -33,762,125,210 (-31.7%).
- Net loss of 32,424,112,960 reduced equity.
- Other factors decreased equity by 1,338,012,250.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-32.42 Billion | -44.62% |
| Other Changes | ₩-1.34 Billion | -1.84% |
| Total Change | ₩- | -31.72% |
Book Value vs Market Value Analysis
This analysis compares Vivozon Healthcare Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.39x to 2.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩599.47 | ₩3230.00 | x |
| 2017-12-31 | ₩424.37 | ₩3230.00 | x |
| 2018-12-31 | ₩919.23 | ₩3230.00 | x |
| 2019-12-31 | ₩905.06 | ₩3230.00 | x |
| 2020-12-31 | ₩766.46 | ₩3230.00 | x |
| 2021-12-31 | ₩2504.91 | ₩3230.00 | x |
| 2022-12-31 | ₩2261.07 | ₩3230.00 | x |
| 2023-12-31 | ₩2158.54 | ₩3230.00 | x |
| 2024-12-31 | ₩2026.75 | ₩3230.00 | x |
| 2025-12-31 | ₩1391.90 | ₩3230.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivozon Healthcare Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54.64%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 2.28x
- Recent ROE (-44.62%) is below the historical average (-28.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -3.83% | -1.08% | 2.24x | 1.58x | ₩-4.69 Billion |
| 2015 | -39.34% | -10.81% | 1.84x | 1.98x | ₩-12.16 Billion |
| 2016 | -7.83% | -2.61% | 1.63x | 1.85x | ₩-4.06 Billion |
| 2017 | -41.42% | -10.93% | 1.68x | 2.26x | ₩-8.28 Billion |
| 2018 | -12.47% | -18.55% | 0.46x | 1.47x | ₩-15.38 Billion |
| 2019 | -25.69% | -62.28% | 0.27x | 1.51x | ₩-38.90 Billion |
| 2020 | -40.59% | -100.37% | 0.18x | 2.30x | ₩-54.53 Billion |
| 2021 | -81.60% | -120.31% | 0.30x | 2.28x | ₩-77.97 Billion |
| 2022 | -37.70% | -77.39% | 0.28x | 1.77x | ₩-50.49 Billion |
| 2023 | -3.23% | -4.71% | 0.41x | 1.67x | ₩-13.76 Billion |
| 2024 | -9.38% | -11.39% | 0.47x | 1.73x | ₩-20.62 Billion |
| 2025 | -44.62% | -54.64% | 0.36x | 2.28x | ₩-39.69 Billion |
Industry Comparison
This section compares Vivozon Healthcare Inc's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $100,225,866,645
- Average return on equity (ROE) among peers: 0.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivozon Healthcare Inc (082800) | ₩72.66 Billion | -3.83% | 1.28x | $162.99 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $298.46 Billion | -3.48% | 0.37x | $6.03 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $105.33 Billion | 1.93% | 1.32x | $33.52 Million |
| NatureCell Co.Ltd (007390) | $39.48 Billion | -1.17% | 0.30x | $688.81 Million |
| Sam-A Pharm. Co. Ltd (009300) | $110.58 Billion | 8.88% | 0.25x | $68.66 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $169.03 Billion | 11.15% | 0.19x | $89.89 Million |
| WooGene B&G Co. Ltd (018620) | $29.85 Billion | -6.92% | 1.60x | $13.13 Million |
| Oscotec Inc (039200) | $26.33 Billion | -13.85% | 0.55x | $990.30 Million |
| EstechPharma Co. Ltd (041910) | $111.39 Billion | 9.84% | 0.11x | $59.21 Million |
| Komipharm International Co. Ltd (041960) | $76.28 Billion | -3.69% | 0.60x | $380.81 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $35.53 Billion | 3.47% | 0.29x | $34.35 Million |
About Vivozon Healthcare Inc
Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications. It also provides LED set linear lamps, including panel lamps, down lights, and flood lights for residential, commercial, and industrial structures, as w… Read more